How Do I Decide When to Consolidate or Diversify my Supply Chain?

In our recurring Ask Our Experts feature, three Medline leaders tackle common customer questions from clinical, financial and operational perspectives.

Angela Carranza, MBA, CST, Medline Director of Clinical Solutions—Periop, Acute Care Sales

When you’re evaluating consolidation versus diversification, decisions should be guided by how a product functions in care delivery and its impact on patients, because not all products are clinically equivalent. A tiered clinical criticality framework, aligned with portfolio-based supply models and healthcare supply risk principles, helps stratify products by clinical impact and disruption risk. For example, IV fluids directly influence hemodynamic stability, whereas non-clinical items carry minimal patient risk. Consolidation makes sense for low-risk, clinically interchangeable products, where standardization improves consistency and efficiency. Diversification is essential for high-acuity, failure-intolerant or preference-sensitive items, where availability and performance directly affect outcomes. The right supply partner can make this balance easier; those with broad portfolios can help standardize where appropriate, while offering flexibility when disruptions occur. Keeping patient impact, substitutability and disruption risk at the center can help ensure decisions are made with the right balance of efficiency and clinical supply resilience.

Brooke Duval, Medline Executive Account Director—Acute Care Sales

The decision to consolidate versus diversify your supply chain is often treated as an either‑or choice, but financially, it doesn’t have to be. The real consideration is how to balance cost control with supply continuity. Consolidation can simplify the financial side of supply management. Fewer distributor relationships typically mean fewer contracts, more consistent pricing and clearer visibility into demand and spend. That visibility can help reduce administrative burden, support better inventory decisions and limit costs tied to freight, invoicing and excess stock. Diversification, however, is about managing risk. Importantly, diversification can exist within a consolidated model. Partnering with a distributor that maintains a broad portfolio of manufactured products and sourcing options can provide built‑in redundancy without the complexity of managing multiple vendors. From a financial standpoint, the goal is a model that limits overhead while still supporting resilience during disruption.

Robert Brandt, Medline Vice President of Prime Vendor Sales Support

Consolidated supply chains can deliver optimal efficiency, lower cost and simplicity. The most important consideration: the partners. Partnerships that deliver value (price/quality), performance (metrics/simplicity) and a committed team impact all healthcare models, especially when deployed across all areas of care with an aligned strategy. A diversified supply chain does not guarantee fewer disruptions. It expands contacts in times of trouble and increases logistical complexity. Diversification does support your resiliency strategy and will fortify a high-performing consolidated supply chain when focused on two key areas: logistics, including bulk storage options, 3PL programs and secondary sourcing relationships; and core/critical SKUs, including identified SKUs, sub options and most importantly visibility to risk.